Jubiliant Life Sciences Ltd has received the final Abbreviated New Drug Application (ANDA) approval for its drug Olmesartan Medoxomil, the generic version of Benicar of Daiichi Sanyo, which is used for treating hypertension.

“This is the second approval that we have received from the USFDA during the current financial year,” the company said in a BSE filing on Tuesday.

As on December 31, 2016, the company had a total of 73 ANDAs for oral solids filed in the US, of which 49 have been approved.

Jubiliant Life Sciences Ltd is an integrated global pharmaceutical and life sciences company engaged in pharma, life science ingredients and drug delivery solutions.

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

Related Pharma